NCT02344004View on ClinicalTrials.gov

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

PHASE3CompletedINTERVENTIONAL

Enrollment

336

Participants

Timeline

Start Date

May 27, 2015

Primary Completion Date

July 3, 2018

Study Completion Date

April 3, 2019

Conditions

Mycobacterium Infections, Nontuberculous

Interventions

DRUG

LAI (Liposomal Amikacin for Inhalation) 590 mg

LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.

All Listed Sponsors

lead

Insmed Incorporated

INDUSTRY

NCT02344004 - Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone | Biotech Hunter | Biotech Hunter